EMA aims to improve the availability of medicines in Europe

Home/Policies & Legislation | Posted 12/10/2018 post-comment0 Post your comment

A European Union (EU) task force, which was set up by European regulators, has published its work programme for 2019/20 and announces a multi-stakeholder workshop.

109 MD002387

The task force was set up by the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) with the aim of improving the availability of medicines in the EU. It includes representatives from the European Commission and interested national competent authorities, the chairs of the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) and Veterinary (CMDv), the GMP/GDP Inspectors Working Group, the Working Group of Communication Professionals (WGCP) and the European Surveillance Strategy Working Group (ESS WG).

Key priorities of the task force include:

  • looking at ways to minimize supply disruptions and avoid shortages by facilitating approval and marketing of medicines using the existing regulatory framework, e.g. using work sharing and reduced timetables when possible
  • developing strategies to improve prevention and management of shortages caused by disruptions in the supply chain, e.g. developing guidance for companies on reporting of shortages
  • encouraging best practices within industry to prevent shortages
  • improving sharing of information and best practices among EU regulatory authorities to better coordinate actions across the EU
  • fostering collaboration with stakeholders and enhancing communication of supply problems to EU citizens.

The task force also announced that it will organize a multi-stakeholder workshop on 8−9 November 2018 to gather stakeholders’ perspectives on how to address availability issues and to include their input into the deliverables of the task force.

Related article
The Common European Submission Platform

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: EMA, HMA

comment icon Comments (0)
Post your comment
Related content
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
USA BIOSIM Act introduction
02 AA010638
Home/Policies & Legislation Posted 17/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010